

Material Information (3176 MEDIGEN?????)

SEQ_NO	1	Date of announcement	2025/07/07	Time of announcement	16:35:05
Subject	Announcement of Final Non-Prosecution Decision Rendered by the Taiwan High Prosecutors Office Regarding Company Executives				
Date of events	2025/07/07	To which item it meets	paragraph 53		
Statement	<p>1.Date of occurrence of the event:2025/07/07</p> <p>2.Company name:Medigen Biotechnology Corp.</p> <p>3.Relationship to the Company (please enter "head office" or "subsidiaries"):head office</p> <p>4.Reciprocal shareholding ratios:N/A</p> <p>5.Cause of occurrence: On December 29, 2022, the Company cooperated with an investigation conducted by the Investigation Bureau of the Ministry of Justice concerning alleged violations of the Securities and Exchange Act by certain Company executives. Following a thorough judicial investigation, the competent authorities determined that no unlawful conduct had occurred, and the case has been lawfully closed with a decision of non-prosecution. The individuals involved ,Chairman Mr. Shi-Chung Chang, former President Mr. Yu-Jen Cheng, and former CFO Mr. Chao-Chuan Ou,have been cleared of all allegations through judicial proceedings, confirming their innocence and lack of any legal wrongdoing.</p> <p>This case had previously been reviewed twice by the Shilin District Prosecutors Office, both resulting in non-prosecution decisions. As of today, the Taiwan High Prosecutors Office has formally affirmed and upheld the non-prosecution rulings. The Company has always prioritized corporate governance, requiring all employees to comply with the law and faithfully perform their duties. The Company hereby issues this announcement in accordance with applicable legal disclosure requirements.</p> <p>6.Countermeasures:none</p> <p>7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):none</p>				